Applications of 6-Chloro-9-Beta-D-(2,3-Isopropylidene)Ribofuranosylpurine in Industrial Manufacturing

As the actual producer of 6-Chloro-9-Beta-D-(2,3-Isopropylidene)Ribofuranosylpurine, our material serves critical roles in nucleoside and pharmaceutical intermediate manufacturing, fine chemicals, and advanced research reagents production. Below, see a detailed overview of reliable downstream industrial scenarios, each with specific compliance, dosage ranges, integration stages, and end products.

1. Nucleoside-Based Antiviral Drug Intermediate Synthesis

Major API manufacturers in the antiviral segment leverage this compound as a protected nucleoside building block. It enables selective chlorination and controlled glycosylation during active pharmaceutical ingredient synthesis, thus supporting production of specific guanine and adenine analogues widely used in commercial antiviral agents.

Industry compliance standards

• Current Good Manufacturing Practice (cGMP; 21 CFR Parts 210-211)
• ICH Q7A for Active Pharmaceutical Ingredients
• Relevant United States Pharmacopeia (USP) monographs for nucleoside drugs
• European Pharmacopoeia quality standards

Typical usage ratio

• Employed at 1.0–1.3 molar equivalents per nucleoside coupling sequence
• Ratio may adjust depending on the targeted nucleoside analogue and purification yield

Downstream process integration

• Introduced in the initial protected nucleoside condensation stage
• Acts as core precursor prior to heterocycle modification

Final product types

• Antiviral pharmaceutical intermediates for drugs such as Acyclovir and Ganciclovir
• Active nucleoside APIs for oral and injectable formulations

2. Custom Oligonucleotide Synthesis

Advanced DNA and RNA synthesis labs and biomanufacturers adopt this raw material for the construction of modified oligonucleotides. Its isopropylidene-protected sugar provides the necessary selectivity for incorporation of rare purine analogues in specialty sequences, facilitating probe and therapeutic oligonucleotide production.

Industry compliance standards

• ICH Q11 for Drug Substances
• ISO 13485 for oligonucleotide manufacturing (medical use)
• USP <1047> for oligonucleotide identity and purity
• ISO 9001:2015 quality management

Typical usage ratio

• Integrated at 0.8–1.0 equivalents per insertion site during solid-phase synthesis cycles
• Adjusted according to automated synthesizer protocols and sequence complexity

Downstream process integration

• Used during phosphoramidite block preparation
• Participates in the stepwise elongation of oligonucleotide chains before final deprotection

Final product types

• Custom DNA/RNA probes for diagnostics
• siRNA strands and aptamers for research and pharmaceutical development
• Gene editing reagents

3. Manufacturing of Anticancer Purine Analogue Intermediates

Process chemists in oncology drug synthesis use the compound as a key protected purine intermediate within multi-step flow chemistries. Its chlorinated structure and sterically-protected ribofuranosyl group confer selectivity for controlled substitution, essential for high-yield generation of active purine derivatives intended for chemotherapy agents.

Industry compliance standards

• GMP Part II (EU Regulation No. 1252/2014 API standards)
• ICH Q3A/B for impurities and genotoxicity
• Environmental, Health and Safety regulations under REACH (EU) and TSCA (US)
• Certificate of Analysis and traceability documentation as per customer audit protocols

Typical usage ratio

• Typically 1.1–1.3 equivalents per synthesis stage
• Process-dependent; adjusted for protecting group removal steps and conversion rates

Downstream process integration

• Feeds into the initial protected nucleoside functionalization stages
• Forms the glycosylated precursor core before chiral resolution and deprotection

Final product types

• Intermediate compounds for 6-thioguanine and mercaptopurine production
• API-grade purine analogues for injectable and oral anticancer drugs

4. Synthesis of Modified Nucleoside Reference Standards

Analytical and reference material suppliers incorporate this compound in the fabrication of certified nucleoside standards. Its defined purity and stability support the calibration of HPLC and LC-MS systems used for quantifying nucleoside APIs and residues in complex matrices.

Industry compliance standards

• ISO/IEC 17025:2017 laboratory accreditation
• USP and Ph.Eur. reference standard requirements
• GLP—Good Laboratory Practice (21 CFR Part 58)
• ICH Q6A specifications for analytical standards

Typical usage ratio

• Generally 1.0 equivalent per target reference batch
• Quantity adapts based on batch scale and required assay accuracy

Downstream process integration

• Used in certified secondary standard synthesis
• Processed via crystallization or chromatography to isolate HPLC-pure standards

Final product types

• Certified nucleoside reference standards for regulatory release testing
• Analytical grade materials for method development in quality control labs

5. Investigational Compound Synthesis for Biotech R&D

Biotechnology innovators and contract research organizations require this protected purine for synthesizing analogues not yet registered as APIs. Its structural features allow for precise manipulation during lead optimization, deuterium labelling, or rare base modification, supporting early candidate validation and patent applications in competitive drug discovery fields.

Industry compliance standards

• ISO 9001:2015 for chemical research production
• Documentation as per OECD Good Laboratory Practice
• Controlled Substances registration if candidate structure applies
• Internal proprietary material traceability SOPs

Typical usage ratio

• Ranges from 0.5–1.2 equivalents, adjusted by synthetic route and reactivity during early-stage screening

Downstream process integration

• Functions in protected nucleoside formation or direct heterocycle derivatization steps
• Applied in batch or flow chemistry apparatus for rapid intermediate generation

Final product types

• Patent-pending nucleoside analogues for early biological screening
• Research-only compounds for in vitro and in vivo proof-of-concept projects